Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Status:
Completed
Trial end date:
2021-08-03
Target enrollment:
Participant gender:
Summary
Double-blind, randomized, placebo-controlled study to explore the safety, tolerability PK
characteristics and early efficacy of ZSP1601 tablets in patients with non-alcoholic
steatohepatitis (NASH).